Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation in Recurrent Wheezing Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects whose parents /legal representative have given written informed consent.~* Both gender~* Subject up to 36 months of age.~* Subjects with recurrent bronchospasms (wheezing attacks); 3 or more exacerbations in the last 12 months~Exclusion Criteria:~* Subjects whose parents/legal representative have not given written informed consent.~* Subjects out of aged range~* Subjects with malignancies or chemotherapy treatment~* Subjects included in another clinical trial in the last 12 months.~* Subject in immunosuppressive or immunostimulatory treatment~* Subjects who have received iv gamma globulin in the past 12 months.~* Subjects diagnosed with candidiasis or fungal recurrent infections.~* Subjects diagnosed with malabsorption syndrome~* Subjects with clinical allergy to common aeroallergens in the geographical area.~* Subjects with hepatitis virus infections, HIV and tuberculosis

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation
- Biological vaccine (Type: EXPERIMENTAL): The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation

Based on this trial design, predict the completion outcome and termination type (if applicable).